

GTB-3550 TriKE™ safely activates and delivers IL-15 to NK cells, but not T cells, in immune suppressed patients with advanced myeloid malignancies, a novel paradigm exportable to solid tumors expressing HER2 or B7H3

J. Miller¹, E. Warlick¹, D. Valleria², R. Wangen³, N. Zorko⁴, P. Hinderlie¹, D. Lewis¹, M. Felices¹;
¹Medicine, Masonic Cancer Center – University of Minnesota, Minneapolis, MN, United States of America, ²Radiation Oncology, Masonic Cancer Center – University of Minnesota, Minneapolis, United States of America, ³Masonic Cancer Center, Masonic Cancer Center – University of Minnesota, Minneapolis, MN, United States of America, ⁴Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, United States of America



Masonic Cancer Center

UNIVERSITY OF MINNESOTA

Comprehensive Cancer Center designated by the National Cancer Institute



Disclosures

- GT BioPharma
 - SAB, Research Support, Consulting, Stock options
- Fate Therapeutics
 - Research Support, Consulting, Stock options
- OnkImmune, Nektar
 - SAB
- Vycellix
 - Consulting, Stock options




Masonic Cancer Center

UNIVERSITY OF MINNESOTA

Comprehensive Cancer Center designated by the National Cancer Institute


Allogeneic NK Cell Adoptive Transfer: Two Decades and Hundreds of Patients



Masonic Cancer Center
UNIVERSITY OF MINNESOTA

¹Miller et al, Blood, 2005; ²Bachanova et al, Blood 2014; ³Cooley et al, Blood Advances 2019



Allogeneic NK Cell Adoptive Transfer: Two Decades and Hundreds of Patients




Masonic Cancer Center
UNIVERSITY OF MINNESOTA

¹Miller et al, Blood, 2005; ²Bachanova et al, Blood 2014; ³Cooley et al, Blood Advances 2019



Replacement Of scFv With Camelid VHH Single Domain Sequences






Efficient





camTriKE better activates NK Cells but not T Cells




2nd Generation TriKE Function In Vivo




Cam16/IL15/scFv HER2 TriKE Highly Effective Against Ovarian




SKOV3/Luc, Human NK Cells




cam1615camB7H3 TriKE Pan Solid Tumor Targeting





Percent CD107a+ NK Cells



Percent IFN-gamma+ NK Cells



BT-12 (Atypical Teratoid/Rhabdoid)



Incucyte-based killing assay. 20,000 OVCAR8-GFP cells were allowed to form a spheroid over 3 days, and then 40,000 NK were added alone or with B7H3 TriKE.

Team Science

University of Minnesota

Laboratory

Martin Felices
Daniel Vallera
Frank Cichocki
Nick Zorko
Bruce Walcheck
Aimee Merino
Bin Zhang
Todd Lenvik
Zachary Davis
Pippa Kennedy
Upasana Arvinda
Emily Chiu
Jake Myers

Faculty/MDs

Mark Juckett
Daniel J Weisdorf
John Wagner
Bruce Blazar
Claudio Brunstein
Veronika Bachanova
Melissa Geller
Joseph Maakaron

GMP Facility

David McKenna, MD
Darin Sumstad
Diane Kadidlo
William Sharkey
Andy Sicheneder



Masonic Cancer Center

UNIVERSITY OF MINNESOTA

Comprehensive Cancer Center designated by the National Cancer Institute